|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-18
|
|
pubmed:abstractText |
Severe acute exacerbation of chronic hepatitis B is a unique clinical presentation with significant morbidity and mortality. Lamivudine was used in most previous studies, but the drug was limited by the development of resistance. Our objective is to study the safety and efficacy of entecavir in patients with severe acute exacerbation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0168-8278
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
236-42
|
|
pubmed:meshHeading |
pubmed-meshheading:21030105-Adult,
pubmed-meshheading:21030105-Aged,
pubmed-meshheading:21030105-Alanine Transaminase,
pubmed-meshheading:21030105-Antiviral Agents,
pubmed-meshheading:21030105-DNA, Viral,
pubmed-meshheading:21030105-Female,
pubmed-meshheading:21030105-Guanine,
pubmed-meshheading:21030105-Hepatitis B, Chronic,
pubmed-meshheading:21030105-Hepatitis B e Antigens,
pubmed-meshheading:21030105-Humans,
pubmed-meshheading:21030105-Lamivudine,
pubmed-meshheading:21030105-Male,
pubmed-meshheading:21030105-Middle Aged,
pubmed-meshheading:21030105-Prospective Studies,
pubmed-meshheading:21030105-Virus Activation
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B.
|
|
pubmed:affiliation |
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
